Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs.

…read more

Source: Bristol-Myers’ oncology star lines up for lung cancer approval, leading the PD-1 pack